Chemomab Therapeutics (CMMB)

• Market cap: $21.1M
• 1 day: -3.45%
• 5 days: 17.11%
• 1 month: -25.33%
• 3 months: -47.66%
• 6 months: -12.50%
• Year to date: -47.42%
• 1 year: 89.83%
• 5 years: 28.74%
• 10 years: -89.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

7% more funds holding

Funds holding: 15 [Q3] → 16 (+1) [Q4]

5% more capital invested

Capital invested by funds: $7.14M [Q3] → $7.53M (+$388K) [Q4]

0.14% less ownership

Funds ownership: 1.58% [Q3] → 1.45% (-0.14%) [Q4]

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 525% upside
• Avg. target: $7 525% upside
• High target: $7 525% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Michael Okunewitch 13% 1-year accuracy 1 / 8 met price target

525% upside $7

Buy Maintained

20 Feb 2025